会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 13. 发明公开
    • 미토콘드리아 기능 조절에 활성을 지닌 트리아졸 유도체
    • 三唑衍生物作为麻醉功能调节剂
    • KR1020130096900A
    • 2013-09-02
    • KR1020120018466
    • 2012-02-23
    • 한국과학기술연구원
    • 민선준조용서배애님이재균이지연정선화박병건
    • C07D403/04C07D249/06A61K31/41A61K31/4025
    • PURPOSE: A triazole derivative is provided to be used as a restorative of mitochondrial dysfunction with effects of treating Alzheimer's diseases, Parkinson's disease, Huntington's disease, ischemic diseases, diabetes, and schizophrenia. CONSTITUTION: A compound is selected among a triazole derivative of chemical formula 1and a pharmaceutically acceptable salt thereof. A pharmaceutical composition for treating Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic disease, diabetes, and schizophrenia contains the compound as an active ingredient. A method for preparing the triazole compound comprises the step of reacting an azide compound of chemical formula 2 and an ethynyl benzene compound of chemical formula 3 by dipolar cycloaddition.
    • 目的:提供三唑衍生物作为线粒体功能障碍的修复剂,具有治疗阿尔茨海默氏病,帕金森病,亨廷顿病,缺血性疾病,糖尿病和精神分裂症的作用。 构成:化合物选自化学式1的三唑衍生物及其药学上可接受的盐。 用于治疗阿尔茨海默病,帕金森病,亨廷顿病,缺血性疾病,糖尿病和精神分裂症的药物组合物含有该化合物作为活性成分。 制备三唑化合物的方法包括通过偶极环加成使化学式2的叠氮化合物与化学式3的乙炔基苯化合物反应的步骤。
    • 15. 发明授权
    • 미토콘드리아 기능 조절제로서의 아릴옥심 유도체
    • ARYLOXIME衍生物作为麻醉功能调节剂
    • KR101267937B1
    • 2013-05-31
    • KR1020120018465
    • 2012-02-23
    • 한국과학기술연구원
    • 민선준배애님조용서이재균김영습최연희이지연
    • C07C251/48A61K31/26A61P25/00
    • PURPOSE: Aryloxime derivatives are provided to show excellent activity as a neuroprotective agent acting on mitochondria, therefore, to be useful as a treatment and prevention agent of diseases such as Alzheimer disease, Parkinson's disease, Huntington disease, ischemic disease, diabetes, and schizophrenia. CONSTITUTION: A chemical is selected from aryloxime derivatives represented by Chemical formula 1, and pharmaceutically acceptable salt thereof. In the chemical formula 1; R^1 represents a 4-8 membered azacyclic group or a 7-9 membered azabicylic group, and the azacyclic or azabicyclic group is able to be substituted with 1-3 substituents selected from C1-6 alkyl and benzyl, or be non-substituted; R^2 and R^3 respectively represent a hydrogen group, a halogen group, a C1-C6 alkyl group, a C1-C6 haloalkyl group, or a C1-C6 alkoxy group; and n is an integer of 0, 1, 2 or 3.
    • 目的:提供芳肟衍生物作为作用于线粒体的神经保护剂具有优异的活性,因此可用作诸如阿尔茨海默病,帕金森病,亨廷顿病,缺血性疾病,糖尿病和精神分裂症等疾病的治疗和预防剂。 构成:选自化学式1表示的芳肟衍生物及其药学上可接受的盐。 在化学式1中; R 1表示4-8元氮杂环基或7-9元氮杂双环基,氮杂环或氮杂双环基团可以被1-3个选自C 1-6烷基和苄基的取代基取代,或被取代 ; R 2和R 3分别表示氢基,卤素基,C 1 -C 6烷基,C 1 -C 6卤代烷基或C 1 -C 6烷氧基; n为0,1,2或3的整数。
    • 17. 发明授权
    • 모세관 전기 영동장치를 이용하여 세포에서 방출되는아질산염을 분석하는 방법
    • 使用本应用程序中的应用程序在本应用程序中使用本应用程序
    • KR100461921B1
    • 2004-12-18
    • KR1020030002928
    • 2003-01-16
    • 한국과학기술연구원
    • 유영숙이지연반은미이세윤
    • G01N27/447
    • PURPOSE: A method for analyzing a nitrite emitted from a cell by using a capillary electrophoresis is provided to reduce cost, time and labor for analyzing the reaction in a cell by using a capillary electrophoresis. CONSTITUTION: A method for analyzing a nitrite emitted from a cell by using a capillary electrophoresis comprises the steps of setting up a condition of a capillary electrophoresis, writing a concentration testing curve of a detecting peak versus a standard material by detecting a nitrite under the set condition, growing a cell on a medium, detecting a nitrite peak emitted from the cell by using a cell growing supernatant, and determining nitrite concentration by applying the nitrite peak to the concentration testing curve.
    • 目的:提供一种通过使用毛细管电泳分析从细胞中释放的亚硝酸盐的方法,以降低通过使用毛细管电泳来分析细胞中的反应的成本,时间和劳力。 本发明公开了一种利用毛细管电泳分析细胞发射的亚硝酸盐的方法,包括以下步骤:建立毛细管电泳条件,通过检测该组下的亚硝酸盐,写出检测峰对标准物质的浓度测试曲线 条件下,在培养基上生长细胞,通过使用细胞生长上清液检测从细胞发射的亚硝酸盐峰值,并通过将亚硝酸盐峰值应用于浓度测试曲线来测定亚硝酸盐浓度。
    • 19. 发明公开
    • 신경보호제로서의 유레아 유도체
    • 尿素类似物作为神经保护剂
    • KR1020130115696A
    • 2013-10-22
    • KR1020120038239
    • 2012-04-13
    • 한국과학기술연구원
    • 추현아배애님김지윤박병건이지연노은주박정은라현화
    • C07D211/42C07D241/28A61K31/44A61P25/00
    • PURPOSE: A urea derivative is provided to selectively suppress the action of mPTP in the brain, thereby being used as a neuroprotective agent which improves the action of the mitochondria. CONSTITUTION: A urea derivative is denoted by chemical formula 1. A method for preparing the urea derivative comprises the steps of making a compound of chemical formula 2 react with isocyanate compounds or isothiocyanate compounds. The compound of chemical formula 2 is prepared by making a compound of chemical formula 3 react with benzyl halide compounds. A pharmaceutical composition for suppressing the action of mPTP contains the urea derivative or a pharmaceutically acceptable salt thereof as an active ingredient. A pharmaceutical composition for treating nervous diseases contains the urea derivative or a pharmaceutically acceptable salt thereof as an active ingredient.
    • 目的:提供尿素衍生物以选择性抑制脑中mPTP的作用,从而用作改善线粒体作用的神经保护剂。 构成:以化学式1表示脲衍生物。制备尿素衍生物的方法包括使化学式2的化合物与异氰酸酯化合物或异硫氰酸酯化合物反应的步骤。 通过使化学式3的化合物与苄基卤化合物反应来制备化学式2的化合物。 用于抑制mPTP作用的药物组合物含有尿素衍生物或其药学上可接受的盐作为活性成分。 用于治疗神经疾病的药物组合物含有尿素衍生物或其药学上可接受的盐作为活性成分。
    • 20. 发明公开
    • 수소저장재료 및 그 제조 방법
    • 氢储存材料及其制造方法
    • KR1020110083994A
    • 2011-07-21
    • KR1020100004006
    • 2010-01-15
    • 한국과학기술연구원
    • 이영수이지연조영환심재혁서진유김동익정우상
    • C01B3/04C01B6/21
    • Y02E60/364
    • PURPOSE: A hydrogen storing material and a method for manufacturing the same are provided to mix metal borohydride with different thermodynamic stabilities and secure the thermodynamic stability, less than the average value of the different thermodynamic stabilities, to the hydrogen storing material. CONSTITUTION: A hydrogen storing material includes lithium borohydride(LiBH_4) and calcium borohydride(Ca(BH_4)_2) by mixing lithium borohydride powder and calcium borohydride powder(S10). The ratio of the lithium borohydride with respect to the calcium borohydride is between 0.25 and 4. The molar ratio of lithium borohydride powder with respect to calcium borohydride powder is between 0.6 and 1. A material selected from a group including catalyst, reaction product of the catalyst and the lithium borohydride, and another reaction product of the catalyst and the calcium borohydride is additionally included.
    • 目的:提供储氢材料及其制造方法,以混合具有不同热力学稳定性的金属硼氢化物,并确保小于不同热力学稳定性的平均值的氢储存材料的热力学稳定性。 构成:通过混合硼氢化锂粉末和硼氢化钙粉末(S10),储氢材料包括硼氢化锂(LiBH_4)和硼氢化钙(Ca(BH_4)_2)。 硼氢化锂相对于硼氢化钙的比例为0.25-4。硼氢化锂粉末相对于硼氢化钙粉末的摩尔比在0.6和1之间。选自包括催化剂,反应产物 催化剂和硼氢化锂,另外还包括催化剂和硼氢化钙的另一反应产物。